Ronald Kirk Huntsman - 30 Jun 2026 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: VVOS
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Sep 2026, 17:04:53 UTC
Prior SEC filing: 27 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman

Key filing fact

Ronald Kirk Huntsman filed Form 4 for Vivos Therapeutics, Inc. (VVOS) on 18 Sep 2026.

Key facts

This page summarizes Ronald Kirk Huntsman's Form 4 filing for Vivos Therapeutics, Inc. (VVOS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Sep 2026, 17:04.

Change

Previous filing in this sequence was filed on 27 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835498 Primary reporting owner

Huntsman Ronald Kirk

Relationship: Chief Executive Officer, Director
Address: 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON
Signature: /s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VVOS transaction

Preferred Stock

Other

Transaction value
Shares: +85,910
Change %
Price: $0.5820^*
Shares after: 85,910
Date: 30 Jun 2026
Ownership: See footnote
Footnotes: F2

VVOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,461
Date: 30 Jun 2026
Ownership: Direct

VVOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 69,600
Date: 30 Jun 2026
Ownership: See footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VVOS transaction Derivative

Warrant (Right to Buy)

Other

Transaction value
Shares: +85,910
Change %
Price: $0.5820^*
Shares after: 85,910
Date: 30 Jun 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 85,910
Exercise price: $0.4560
Footnotes: F2

VVOS holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 359,754
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 359,754
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.

Footnote F2

On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.

Footnote F3

Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).